The 3 most recent market catalysts affecting $ANTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting
AN2 Therapeutics is announcing its plan to present clinical and nonclinical data for epetraborole at the SOHO 2026 Annual Meeting. This matters because the presentation of data, es…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
AN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate
AN2 Therapeutics (ANTX) announced its Q2 earnings, reporting a loss of $(0.18) per share, which was a substantial beat against the analyst consensus of $(0.27). This positive surpr…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 60
Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9
Guggenheim analyst Brad Canino initiated coverage on AN2 Therapeutics (ANTX) with a 'Buy' rating and a $9 price target. This event is significant as new analyst coverage, especiall…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.